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Abstract 
Aim: To assess the cost-effectiveness of LUCAS-2, a mechanical device for cardiopulmonary 
resuscitation (CPR) as compared to manual chest compressions in adults with non-traumatic, out-of-
hospital cardiac arrest. 
Methods: We analysed patient-level data from a large, pragmatic, multi-centre trial linked to 
administrative secondary care data from the Hospital Episode Statistics (HES) to measure  healthcare 
resource use, costs and outcomes in both arms. A within-trial analysis using quality adjusted life years 
derived from the EQ-5D-3L was conducted at 12-month follow-up and results were extrapolated to 
the lifetime horizon using a decision-analytic model.   
Results: 4471 patients were enrolled in the trial (1652 assigned to the LUCAS-2 group, 2819 
assigned to the control group). At 12 months, 89 (5%) patients survived in the LUCAS-2 group and 
175 (6%) survived in the manual CPR group. In the vast majority of analyses conducted, both within-
trial and by extrapolation of the results over a lifetime horizon, manual CPR dominates LUCAS-2. In 
other words, patients in the LUCAS-2 group had poorer health outcomes (i.e. lower QALYs) and 
incurred higher health and social care costs. 
Conclusion: Our study demonstrates that the use of the mechanical chest compression device 
LUCAS-2 represents poor value for money when compared to standard manual chest compression in 
out-of-hospital cardiac arrest.  
 
Keywords: Cardiac arrest; mechanical compression; cost-effectiveness; health economics  
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Introduction 
National Health Service (NHS) Ambulance Services attend approximately 60,000 cardiac arrests each 
year in the UK. (1) Resuscitation is attempted in only under half of the cases and the overall survival 
to hospital discharge is only approximately 8%. While functional survival after cardiac arrest is 
generally good (2), survivors may experience post-arrest problems, including anxiety, depression, 
posttraumatic stress, and difficulties with cognitive function.(3) However, despite the annual death 
toll exceeding that of dementia, stroke or lung cancer, there has been relatively little investment in 
research in this condition.  This has created a relatively weak evidence base compared to other 
diseases. (4)  High mortality and the challenges of accurate prediction of patient outcomes mean that 
important resources are invested in treating cardiac arrest patients without clear assessment of the 
potential benefits. A recent single-centre micro-costing study has estimated that the cost per survivor 
to hospital discharge was £50,000, with a cost per quality-adjusted life years (QALY) of £16,000 
among patient with good neurological outcomes. (5) Overall, only a few studies assessed the costs of 
out-of-hospital of cardiac arrest and the cost-effectiveness of related interventions. (6-11)   
A critical step of the resuscitation process is early cardiopulmonary resuscitation (CPR), i.e. 
the combination of chest compressions and ventilations. CPR can be started by bystanders and is 
typically taken over by emergency services. (12) Current resuscitation guidelines highlight the 
importance of high quality CPR for ensuring optimal outcomes from cardiac arrest. (13) In this 
context, several mechanical devices have been proposed that are able to provide compressions of a 
standard depth and frequency for long periods without interruption or fatigue. In addition, these 
devices free emergency medical personnel for other tasks. The LUCAS-2 (Lund University 
Cardiopulmonary Assistance System) is a mechanical device that provides automatic chest 
compressions, manufactured in Sweden by PhysioControl.  It delivers sternal compression at a 
constant rate to a fixed depth and has been on the market since 2002 in Europe. The primary objective 
of this study was to assess the cost-effectiveness of the LUCAS-2 device versus manual CPR using 
data from a large pragmatic multi-centre trial. (14)  While several other studies have assessed the 
effectiveness of mechanical chest compression devices in out-of-hospital cardiac arrest (15-18), this 
study is the first comprehensive economic evaluation in this area. The analysis also provides useful 
costs and health-related quality-of-life (HRQoL) estimates that will be of use in future economic 
models. 
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Methods 
Overview of the analysis 
The study was based on costs and outcomes from a large multi-centre randomised controlled 
trial of mechanical versus manual chest compression (CPR), the PARAMEDIC trial. (19) Briefly, this 
was a pragmatic, cluster-randomised open-label trial including adults with non-traumatic, out-of-
hospital cardiac arrest from four UK Ambulance Services (West Midlands, North East, Wales, South 
Central). Ninety one urban and semi-urban ambulance stations were selected for participation. 
Clusters were ambulance service vehicles, which were randomly assigned (1:2) to LUCAS-2 or 
manual CPR. Patients received LUCAS-2 mechanical CPR or manual CPR according to the first trial 
vehicle to arrive on scene. The trial was approved in accordance with the requirements of the Mental 
Capacity Act (2005) for England and Wales by the Coventry Research Ethics Committee (ref 
09/H1210/69). Enrolment proceeded with waiver of informed consent; patients discharged from 
hospital were invited to take part in the follow up and written consent obtained. (14) The economic 
evaluation was conducted to assess the cost-effectiveness of LUCAS-2 compared to manual CPR 
during resuscitation by ambulance staff after out-of-hospital cardiac arrest. It consisted of two 
complementary sets of analyses: a within-trial analysis over the 12 months trial period and a decision-
analytic model built to extrapolate the results over the expected lifetime of trial participants. The 
analyses followed best practice guidelines (20), were conducted from the UK NHS perspective and 
report cost per incremental quality-adjusted life year (QALY) of LUCAS-2 compared to usual care 
(i.e. manual CPR). Missing data for both resource use and health outcomes were handled using 
multiple imputation (see Technical Appendix).  
Resource use and costs  
The costs considered in this analysis included intervention costs and the costs associated with the use 
of health care services along the patient pathway.  Intervention costs were defined as the additional 
costs of the LUCAS-2 device as compared to manual CPR. Micro-costing was used to establish the 
cost of LUCAS-2 and determine the relevant cost per application. The following cost elements were 
considered:  1) the cost of purchasing the device and accessories; 2) the cost of fitting the device to 
the ambulance; 3) maintenance costs; and 4) initial and on-going staff training costs. A product 
lifespan of eight years was assumed in the calculations. Total costs were divided by the total number 
of applications estimated from trial data to obtain an estimate of the cost per application 
(Supplementary Table S1).  
Resource use included hospital inpatient stays, A&E admissions and outpatient visits, and the use of 
primary care-based and community-based health and social care services, such as GP and social 
worker visits. Various data sources were combined to obtain a patient-level estimate of resource use 
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along the care pathway. Data on the use of hospital services were obtained through linkage with the 
Hospital Episode Statistics (HES) data set (Copyright © 2014, re-used with the permission of the 
Health and Social Care Information Centre. All rights reserved). We extracted data from the HES for 
study participants from cardiac arrest to 12 months after randomisation. The dataset records 
information on inpatient length of stay (LOS) (ICU and general ward), in-person and telephone 
outpatient visits, and A&E admissions. As intensive care is likely to account for a large share of the 
costs of cardiac arrest, data on ICU LOS were also extracted from the Intensive Care National Audit 
and Research Centre (ICNARC) dataset and complementary analyses were conducted using this 
alternative data source. Patients who died in hospital within 24 hours (i.e. LOS<1) were considered as 
having spent one day in ICU. 
Following hospital discharge, healthcare resource use questionnaires were completed by 
surviving patients at three and twelve months post cardiac arrest. Patients were asked about their use 
of health and social services during the previous 3 months, including further inpatient and outpatient 
care and primary- and community-based health and social services. We used the average resource 
utilisation between the initial (0-3 months) and final (9-12 months) period to impute resources 
utilisation for the 6 months period during which post-discharge resource use data were not collected 
(i.e. between 3 and 9 months post cardiac arrest). Patients who died within 3 months were assumed to 
have incurred no post-discharge costs. Of note, this represents only a small proportion of patients as 
most patients either died within days, or survived beyond 3 months. Resource use was multiplied by 
the relevant unit costs extracted from national reference costs. (21, 22) (Supplementary Table S2). 
Health outcomes 
Quality-adjusted life years (QALYs) reflect both duration and quality of life and their estimation 
requires the production of utility weights for each health state observed in the trial population. 
HRQoL was assessed using the EQ-5D-3L which has been validated for use in the critical care patient 
group. (23) Surviving patients completed the EQ-5D-3L at three and twelve months post cardiac 
arrest. The EQ-5D-3L responses were converted to health-state utility values using the UK tariff. (24) 
Utility values were combined with survival information to calculate QALYs for the trial period using 
an area under the curve (AUC) approach. As patients were unable to complete the measure at baseline 
(i.e. cardiac arrest), estimates had to be made of their baseline utility level. Following strategies 
previously employed in studies that had dealt with this scenario (25-27), we assumed that patients 
who experienced a cardiac arrest had a baseline utility value of ‘0’, which is equivalent to dead. We 
then assumed a linear transition from ‘0’ to the 3-month utility value and similarly from the 3-month 
to the 12-month utility value. A utility weight of ‘0’ was assigned to patients who died within 3 
months. Alternative assumptions were explored in sensitivity analyses. 
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Cost-effectiveness analysis  
The within-trial analysis aimed to determine the cost-effectiveness of LUCAS-2 compared to manual 
chest compression over the period of the trial, i.e. from cardiac arrest to 12 months follow-up. Neither 
costs nor QALYs were discounted given the 12-month time period. To extrapolate costs and outcomes 
over a lifetime horizon, we built a decision-analytic model (28), whose structure, parameters and 
assumptions are presented is detail in the Technical Appendix. Incremental cost-effectiveness ratios 
(ICERs) were calculated by dividing the difference in mean cost between the two arms by the 
difference in mean QALYs between the two arms. Thus the ICER represents the cost per QALY 
gained.  ICERs below the NICE willingness to pay threshold of £20,000 indicate cost-effectiveness. 
Sensitivity analyses were performed for both the within-trial and long-term analyses (see Technical 
Appendix).  
 
Results 
Trial participants 
Among the 4771 patients enrolled in the study, 1652 were assigned to the intervention group 
(LUCAS-2) and 2819 were assigned to the control group (manual CPR). During the trial, 985 (60%) 
patients in the intervention group received LUCAS-2 and 11(<1%) patients in the control group 
received mechanical CPR. (14) At 3 months, 96 (6%) patients survived in the LUCAS-2 group and 
182 (6%) survived in the control group. At 12 months, 89 (5%) patients survived in the LUCAS-2 
group and 175 (6%) survived in the manual CPR group. Of the 278 surviving patients at 3 months, 
146 (53%) completed the EQ-5D questionnaire and 145 (52%) completed the resource use 
questionnaire. At 12 months, among the 266 surviving patients, 143 (54%) completed the EQ-5D-3L 
questionnaire and 139 (52%) completed the resource use questionnaire. 
Costs 
Table 1 provides an overview of the costs along the care pathway for both trial arms. In the complete 
case analysis, the mean cost to the NHS at one year was higher in the LUCAS-2 group (£1,400) than 
in the control group (£1,294), giving rise to an incremental cost of £107, with ICU costs being the 
main cost driver. Overall, mean costs in each category was higher in the LUCAS-2 group than in the 
manual CPR group. Multiple imputation gave rise to higher cost estimates in both groups. Using the 
imputed data, we calculated the total cost in each patient group (i.e. the sum of all costs across all 
patients) that we divided by the number of one-year survivors in each group (i.e. 175 in the manual 
CPR arm and 89 patients in the LUCAS-2 arm) and obtained an estimate of the cost per one-year 
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survivor of £32,560 in the manual CPR arm and of £52,548 in the LUCAS-2 arm. This difference is 
driven by the difference in one-year survival rates (i.e. 6.2% vs. 5.4%) and mean one-year cost (i.e. 
£2,021 vs. £2,831) between the two arms.  
Health-related quality of life 
HRQoL scores derived from the 3 months and 12 months EQ-5D-3L questionnaires are shown in 
Table 2. At both follow-up periods, HRQoL was higher in the manual CPR group than in the LUCAS-
2 group (p<0.05). Overall, changes in utility between the 3 month and 12 month assessments were not 
statistically significant. The table also reports the mean QALYs over one year accrued by patients in 
both groups based on the AUC approach and calculated using both the complete case analysis and the 
imputed data. The mean one-year QALYs is small due to the high one-year mortality rate in the 
sample (>95%). As expected, multiple imputation gave rise to higher mean QALYs in both groups. 
The difference in mean QALYs between groups is small, with patients in the manual CPR group 
having a higher average QALYs than patients in the LUCAS-2 group. HRQoL of survivors at 12 
months was also estimated by neurological outcome status (i.e. CPC score). We found a significant 
difference in HRQL between patients with good neurological outcome (CPC score of 1 or 2) (mean: 
0.75) and patients with poor neurological outcome (CPC of 3 or 4) (mean: 0.47).  
Cost-effectiveness  
Table 3 presents the cost-effectiveness results, showing the incremental costs and QALYs for each 
arm of the trial, as well as the corresponding ICER. At one-year, we found an incremental QALY of -
0.0072 and an incremental cost of £107, which indicates that LUCAS-2 is dominated by manual chest 
compression (dominance means that LUCAS-2 is more costly and less effective than manual chest 
compression). When a per-protocol analysis was conducted instead, manual compression still 
dominated and the conclusions remain unchanged when QALYs were derived using SF-12 instead of 
EQ-5D-3L, and when the ICNARC dataset instead of HES was used to derive ICU costs. Overall, the 
results consistently suggest that manual chest compression dominates LUCAS-2 in this patient group. 
Interpretation should however be tempered by the very small between-group QALY differences and 
the relatively small differences in costs. In Figure 1, we present the results of the 10,000 bootstrap 
replications in the cost-effectiveness plane for the analysis based on multiple imputation. The 10,000 
estimates are spread mainly in the north-west quadrant of the cost-effectiveness plane; it is, however, 
worth noting that QALY losses are minimal.  
The lifetime cost-effectiveness results obtained using the Markov model are presented in Table 4. The 
base case analysis is based on a cohort of patients aged 60, followed over 40 years, which corresponds 
to the average age of patients who survived at one year. Results suggest that LUCAS-2 is dominated 
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by manual CPR, with an incremental cost of £ 2,376.4 and an incremental QALY of -0.1286. This 
finding is robust to a range of sensitivity analyses as shown in the table. Figure 2 shows results from 
the probabilistic sensitivity analysis that takes parameter uncertainty into account. The CEAC indicate 
that the probability that LUCAS-2 is cost-effective is about 25 per cent, irrespective of the value of 
the threshold used.  The flat shape of the CEAC is explained by the fact that most iterations lie in the 
North-West quadrant of the cost-effectiveness plane. (29)  
 
Discussion  
This study is the first to provide evidence on the cost-effectiveness of mechanical chest compression 
as compared to manual CPR. It demonstrates that the use of the mechanical chest compression device 
LUCAS-2 represents poor value for money in out-of-hospital cardiac arrest. In the vast majority of 
analyses conducted, both within-trial and by extrapolation of the results over a lifetime horizon, 
manual CPR dominates LUCAS-2. In other words, patients in the LUCAS-2 group had poorer health 
outcomes and incurred higher health and social care costs. The cost-effectiveness results are driven by 
worse neurological outcomes and lower survival in the LUCAS-2 group as compared to manual CPR. 
Results resonate with previously published short-term clinical outcomes observed in the 
PARAMEDIC trial (14) and are in line with several other randomised trials that have investigated the 
effectiveness of mechanical chest compression (15-18) and that found no consistent evidence of 
survival benefits and highly heterogeneous effects in terms of neurological outcomes.  On the basis of 
there being approximately 28,000 resuscitation attempts in England annually, introducing mechanical 
CPR across English Ambulance Services would likely cost £6.5m per year.  Such costs in the absence 
of evidence of effectiveness are unlikely to be justifiable.  
Potential explanations for worse outcomes in the LUCAS-2 group include interruptions in CPR during 
device deployment that could cause reduced cardiac and cerebral perfusion and possible delay in the 
time to first shock due to the deployment of LUCAS-2.  The pragmatic design of the PARAMEDIC 
trial meant that paramedics received focus training (average 1 hour) similar to the approach that 
would be taken to introducing new technology into NHS Ambulance Services.  More intensive initial 
training, regular re-training adopting a “pit-stop” approach with on-going CPR quality monitoring 
may reduce potentially deleterious interruptions to CPR associated with device deployment. (30, 31)  
In the CIRC trial paramedics received 4 hour initial training, supplemented by refresher training and 
continuous CPR quality monitoring and feedback throughout the study period. (32)  This additional 
training will have increased costs associated with mechanical CPR. The on-going CPR quality 
monitoring programme in the CIRC trial demonstrated that the device was deployed with minimal 
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interruptions to chest compressions, but similar to PARAMEDIC and LINC trial found no difference 
in overall survival. (18)  
Our analysis was primarily based on high quality data collected alongside a large cluster randomised 
trial, and therefore has high internal validity compared to economic studies that rely exclusively on 
modelling. In addition, linkage with large administrative datasets, including the Hospital Episodes 
Statistics data was used to obtain resource use estimates that are more accurate than those obtained 
using retrospective surveys of patients. The importance of such data is crucial given the high mortality 
rate in the trial. The long-term decision model relied on a number of assumptions and existing 
evidence was scarce for some parameters. However, the majority of the key parameters were derived 
from trial data. We are therefore confident that our analyses captured the most relevant relative costs 
and outcomes of LUCAS-2 as compared to manual CPR. Also, our study provides costs and quality-
of-life estimates that can be used in other economic evaluations in cardiac arrest patients/cardiac 
arrest interventions/technology.  
One aspect of costs not considered in our study was the influence of mechanical chest compression 
and injuries to staff involved in the resuscitation attempt. Manual CPR is a physically demanding 
tasks and a survey reported in the literature indicate that approximately 25% of staff sustain back 
injuries during CPR. (33, 34) Advantages of a mechanical CPR device are that they have the potential 
to limit the exposure of staff to periods of prolonged CPR, although require additional heavy 
equipment to be carried to and from the scene of the cardiac arrest.  Ambulance vehicle crashes, 
although fortunately rare (no incidents were reported during our study), have the potential to cause 
significant injuries to staff, particularly if un-restrained by a seat belt.  A mechanical CPR device 
provides staff with the opportunity to use safety belts unlike performing manual CPR. Also, 
availability and deployment of LUCAS-2 may also mean fewer staff are required at scene to manage 
the resuscitation attempt, therefore releasing resources. As our data did not allow us to capture these 
potential benefits of mechanical CPR, there is a risk that our study slightly overestimates the net cost 
of the technology. However, it is unlikely that the presence of the compression device means that only 
one paramedic would be required on scene and that therefore a lower cost would be necessarily 
associated with that scenario. Even if that were the case, the associated cost savings would be below 
£100 per application, considering average intervention time observed in the trial. Also, it is unclear 
whether the effectiveness observed in the trial would be comparable with only one paramedic 
operating the device.  
Meta-analysis from four large and one smaller randomised trial provide consistent evidence that the 
routine use of mechanical CPR in out of hospital cardiac arrest does not improve clinical outcomes 
(35).  These findings are consistent with the International Liaison Committee On Resuscitation 
(ILCOR) treatment recommendation against the routine use of mechanical CPR devices. (36)  ILCOR 
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suggest that mechanical CPR devices may continue to have a role where manual chest compressions 
are impossible or compromise rescuer safety.  Future research could usefully focus on refining the 
indications and cost effectiveness of mechanical CPR in these settings.  
Conclusions 
This study provides evidence that the use of the mechanical chest compression device LUCAS-2 
represents poor value for money in out-of-hospital cardiac arrest. 
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Legends to Figures 
Figure 1: Cost-effectiveness plane (MI analysis – Based on 10,000 Bootstrap replications) 
 
Figure 2: Cost-effectiveness acceptability curves for LUCAS-2 compared with manual CPR 
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Tables  
Table 1 One-year costs by treatment arm 
 Manual CPR LUCAS 
 n n missing mean (£) 95% CI min Max n n missing mean (£) 95% CI min Max 
Complete-case data             
Costs to the NHS 
over 1 year 
2,690 129 1,294.0 1,152.4-1,435.7 0 41,945 1,577 75 1,400.7 1,131.2-1,670.3 0 123,660 
ICU costs 2,762 57 959.2 826.8-1,091.6 0 59,426 1,622 30 1,221.8 766.2-1,677.5 0 317,860 
Other hospital costs 
(A&E, outpatient, 
general ward) 
2,772 47 521.5 428.6-614.3 0 75,767 1,619 33 585.0 386.0-784.0 0 74,276 
Hospital costs 2,732 87 1,318.0 1,136.3-1,499.8 0 101,928 1,599 53 1,540.3 1,083.4-1,997.2 0 318,327 
Community-based 
health and social 
care costs 
2,716 103 31.9 23.1-40.6 0 8,834 1,593 59 91.1 21.2-160.9 0 50,138 
Imputed data             
Costs to the NHS 
over 1 year 
2,819 - 2,021.3 1,772.3-2,270.2 0 41,945 1,652 - 2,831.0 2,149.6-3,512.3 0 123,660 
ICU costs 2,819 - 1,102.1 947.0-1,257.2 0 59,426 1,652 - 1,447.3 883.4-2,011.1 0 317,860 
Other hospital costs 
(A&E, outpatient, 
general ward) 
2,819 - 604.0 478.8-729.1 0 75,767 1,652 - 724.6 507.5-941.7 0 74,276 
Hospital costs 2,819 - 1,706.1 1,477.5-1,934.6 0 101,928 1,652 - 2,171.8 1,525.6-2,818.0 0 318,327 
Community-based 
health and social 
care costs 
2,819 - 108.8 37.9-179.6 0 8,834 1,652 - 287.4 111.8-463.0 0 50,138 
             
Total costs to the 
NHS divided by the 
number of 1 year 
survivors 
175 - 32,560 28,551-36,569   89 - 52,548 39,908-65,188   
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Table 2 – HRQL by treatment arm 
  Manual 
CPR 
  LUCAS-2  
 n Mean 95% CI n Mean 95% CI 
Utility score among 
survivors 
      
3 months 99 0.780 0.732-0.828 47 0.647 0.555-0.738 
12 months 95 0.761 0.712-0.810 48 0.639 0.542-0.736 
       
QALY over 12 months       
Complete case 2,741 0.026 0.021-0.031 1,609 0.018 0.013-0.024 
Imputed 2,818 0.042 0.036-0.048 1,652 0.033 0.026-0.040 
 
Table3 – ICERS: within-trial analysis 
Analysis n Incremental cost (£) Incremental 
QALY 
ICER 
Multiple imputation (ITT) 4,771 809.6 -0.0093 Manual CPR 
dominatesb) 
Complete case (ITT) 4,267 106.7 -0.0072 Manual CPR 
dominates 
Complete case (ITT, average group 
cost for outliers) 
4,267 39.2 -0.0067 Manual CPR 
dominates 
Multiple imputation (per-protocol) 3,793 495.9 -0.0142 Manual CPR 
dominates 
Complete case (per-protocol) 3,391 296.4 -0.0070 Manual CPR 
dominates 
Alternative QALY calculationa) 
 
4,771 809.6 -0.0091 Manual CPR 
dominates 
ICU resource use derived using 
ICNARC dataset 
4,771 934.2 -0.0093 Manual CPR 
dominates 
QALY derived with SF-12 (complete 
case) 
4,267 106.7 -0.0046 Manual CPR 
dominates 
CACE (complete case) 4,267 177.8 -0.012 Manual CPR 
dominates 
a) Instead of incurring 0 QALYs, patients who died within 3 months were imputed QALYs based on their total 
number of survival days to which we assigned a utility corresponding to the average 3-month utility in our sample. 
b) A technology/treatment is said to dominate an alternative when it is less expensive and more effective than the 
alternative. 
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Table 4 – ICERS: Markov model 
Analysis Incremental cost (£) Incremental 
QALY 
ICER 
Base case analysis (age 60 cohort) £2,376.4 -0.1286 Manual CPR dominates 
    
One-way sensitivity analyses    
Sensitivity to costs    
+20% of costs £2,851.6 -0.1286 Manual CPR dominates 
-20% of costs £1,901.1 -0.1286 Manual CPR dominates 
Sensitivity to QALY    
+20% of QALY £2,376.4 -0.1543 Manual CPR dominates 
-20% of QALY £2,376.4 -0.1029 Manual CPR dominates 
Sensitivity to one-year mortality    
+20% one-year mortality -£3,987.5 -0.0187 £213,014 per QALY 
-20% one-year mortality £10,603.8 -0.2401 Manual CPR dominates 
 
 
